Trop2-targeted therapy in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Immunotherapy

Background:

• Human trophoblastic cell surface antigen 2 (Trop2) is a cell surface glycoprotein overexpressed in various cancers, including breast cancer.
• Trop2's role in tumor proliferation, invasion, and metastasis makes it a significant therapeutic target.
• High Trop2 expression in triple-negative breast cancer (TNBC) and other subtypes underscores its clinical relevance.

Purpose of the Study:

• To review the structure and function of Trop2.
• To discuss major Trop2-targeted antibody-drug conjugates (ADCs) and novel agents.
• To provide an overview of clinical trials and future directions in Trop2-targeted cancer therapy.

Main Methods:

• Literature review of Trop2 structure, function, and expression in cancer.
• Analysis of clinical trial data for Trop2-targeted therapies.
• Synthesis of information on approved and investigational Trop2-targeted agents.

Main Results:

• Trop2 is a validated target across breast cancer subtypes, especially TNBC.
• Trop2-targeted ADCs, such as Sacituzumab govitecan, have demonstrated efficacy in metastatic breast cancer.
• Several novel Trop2-targeted agents are under investigation, showing promise for future treatments.

Conclusions:

• Trop2-targeted therapy represents a significant advancement in breast cancer treatment, particularly for TNBC.
• The development of Trop2-targeted ADCs and other agents offers new hope for patients with limited treatment options.
• Continued research and clinical trials are crucial for optimizing Trop2-targeted strategies and expanding their application.